Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/CnL0hUKAnvE/231253.php
Monday, 18 July 2011
AiCuris' Novel HSV Compound AIC316 Shows Efficacy In Phase II
Phase II results for AiCuris' novel non-nucleosidic herpes simplex virus (HSV) inhibitor AIC316 reveal safety and efficacy in persons with genital herpes. The data were presented at the 19th ISSTDR Meeting (International Society for Sexually Transmitted Diseases Research) in Quebec, Canada, by the coordinating investigator of the trial, Professor Anna Wald from the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, USA. 156 HSV-2 positive participants (105 women and 51 men) were randomized between May 2010 and October 2010 at seven sites in the US...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment